Table 2 Names of the assessed autoimmune diseases and their incidence rates during periods A-C
Characteristic | Overall AID, | 2020–2022 (Group C), | 2014–2016 (Group A), | 2017–2019 (Group B), |
|---|---|---|---|---|
N = 4,591 | N = 1,502 | N = 1,497 | N = 1,592 | |
Ankylosing spondylitis | 82 (1.8%) | 22 (1.5%) | 28 (1.9%) | 32 (2.0%) |
APLA syndrome | 342 (7.4%) | 117 (7.8%) | 121 (8.1%) | 104 (6.5%) |
Arthritis | 1,056 (23%) | 310 (21%) | 375 (23%) | 371 (23%) |
Bechet disease | 23 (0.5%) | 5 (0.3%) | 11 (0.7%) | 7 (0.4%) |
Celiac disease | 1,305 (28%) | 474 (32%) | 524 (32%) | 307 (19%) |
Juvenile dermatomyositis, polymyositis | 5 (0.1%) | 1 (< 0.1%) | 1 (< 0.1%) | 3 (0.2%) |
Diabetes mellitus type 1 | 267 (5.8%) | 63 (6.1%) | 92 (5.8%) | 112 (6.8%) |
Familial mediterranean fever | 19 (0.4%) | 6 (0.4%) | 5 (0.3%) | 8 (0.5%) |
Guillain–barre syndrome | 28 (0.6%) | 7 (0.5%) | 14 (0.9%) | 7 (0.4%) |
IgA vasculitis | 305 (6.6%) | 84 (6.6%) | 93 (6.8%) | 128 (8.0%) |
Inflammatory bowel disease | 442 (9.6%) | 143 (9.6%) | 148 (9.8%) | 151 (9.5%) |
ITP | 21 (0.5%) | 9 (0.6%) | 9 (0.6%) | 3 (0.2%) |
Kawasaki disease | 52 (1.1%) | 19 (1.3%) | 17 (1.0%) | 16 (1.0%) |
Morphea | 102 (2.2%) | 35 (2.3%) | 35 (2.2%) | 32 (2.2%) |
Multiple sclerosis | 33 (0.7%) | 7 (0.5%) | 13 (0.8%) | 13 (0.8%) |
Psoriasis | 225 (4.9%) | 61 (4.1%) | 84 (5.4%) | 80 (5.0%) |
Raynaud | 245 (5.3%) | 94 (6.3%) | 66 (4.4%) | 85 (5.3%) |
Sarcoidosis | 3 (< 0.1%) | 1 (< 0.1%) | 1 (< 0.1%) | 4 (< 0.1%) |
Systemic lupus erythematosus | 21 (0.5%) | 9 (0.6%) | 9 (0.6%) | 3 (0.2%) |
Systemic sclerosis | 5 (0.1%) | 3 (0.2%) | 0 (0%) | 2 (0.1%) |
Uveitis, panuveitis | 8 (0.2%) | 4 (0.2%) | 1 (< 0.1%) | 3 (0.2%) |
Vasculitisa | 2 (< 0.1%) | 0 (0%) | 0 (0%) | 2 (< 0.1%) |